Pharsight

1. Flo-pred patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6102254	TARO	Pharmaceutical compositions in semisolid form and a device for administration thereof	Mar, 2013 (11 years ago)
US5881926	TARO	Pharmaceutical compositions in semisolid form and a device for administration thereof	Mar, 2016 (8 years ago)
US6656482	TARO	Spill resistant pharmaceutical system	Jun, 2018 (5 years ago)
US6071523	TARO	Spill resistant pharmaceutical compositions in semi-solid form	Jun, 2018 (5 years ago)
US6399079	TARO	Spill resistant pharmaceutical compositions in semi-solid form	Jun, 2018 (5 years ago)
US7799331	TARO	Oral suspension of prednisolone acetate	Oct, 2028 (4 years from now)

Market Authorisation Date: 17 January, 2008

Treatment: Treatment of asthma

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
EQ 15MG BASE/5ML	SUSPENSION;ORAL	Discontinued
EQ 5MG BASE/5ML	SUSPENSION;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7560445	TARO	Process for preparing malathion for pharmaceutical use	Feb, 2027 (2 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7977324	TARO	Process for preparing malathion for pharmaceutical use	Aug, 2026 (2 years from now)

Market Authorisation Date: 02 August, 1982

Treatment: Treatment of patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.005	16 Mar, 2011	1	23 May, 2012	01 Feb, 2027	Deferred

Strength	Dosage	Availability
0.5% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	LOTION;TOPICAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5919479	TARO	Noninvasive dermal anesthetics	Jul, 2015 (8 years ago)
US6528086	TARO	Methods and apparatus for drug delivery involving phase changing formulations	Sep, 2019 (4 years ago)
US10350180	TARO	Solid-forming local anesthetic formulations for pain control	Jan, 2031 (6 years from now)
US10603293	TARO	Solid-forming local anesthetic formulations for pain control	Jan, 2031 (6 years from now)
US10751305	TARO	Solid-forming topical formulations for pain control	Jan, 2031 (6 years from now)

Market Authorisation Date: 29 June, 2006

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
7%;7%	CREAM;TOPICAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5990100	TARO	Composition and method for treatment of psoriasis	Mar, 2018 (6 years ago)
US8715624	TARO	Stable liquid desoximethasone compositions with reduced oxidized impurity	May, 2026 (2 years from now)
US8277780	TARO	Stable liquid desoximethasone compositions with reduced oxidized impurity	Sep, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Apr 11, 2016

Market Authorisation Date: 11 April, 2013

Treatment: Treatment of plaque psoriasis in patients 18 years of age or older

Dosage: SPRAY;TOPICAL